EspeRare and Dermelix partner to tackle rare pediatric genetic diseases

EspeRare and Dermelix partner to tackle rare pediatric genetic diseases

23.4.2019 – The Geneva-based EspeRare Foundation and Dermelix Biotherapeutics have entered a partnership to develop DMX-101, a new therapy for the treatment of X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED), a rare pediatric genetic diseas.

read more on startupticker